harvey
j
alter
susan
l
stramer
b
roger
dodd
b
follow
devast
effect
bloodtransmit
human
immunodefici
viru
hiv
blood
establish
becom
increasingli
vigil
emerg
reemerg
new
threat
safeti
blood
suppli
mani
agent
fulfil
broad
definit
emerg
bloodtransmit
infect
includ
west
nile
viru
wnv
trypanosoma
cruzi
plasmodium
spp
babesia
spp
parvoviru
dengu
viru
prion
caus
variant
creutzfeldjacob
diseas
vcjd
agent
human
herp
kaposi
sarcoma
viru
borellia
lyme
diseas
perhap
avian
flu
viru
known
virem
phase
yet
prove
transfusiontransmit
wake
threat
transfus
servic
use
varieti
donor
screen
intervent
includ
serolog
assay
nucleic
acid
assay
geograph
exclus
base
potenti
exposur
ultim
safeguard
may
preemptiv
pathogen
inactiv
strategi
disrupt
nucleic
acidcontain
agent
though
prion
consider
effort
resourc
invest
arena
current
singl
techniqu
effect
inactiv
liquid
cellular
blood
product
toxic
issu
complet
resolv
blood
suppli
remark
safe
risk
major
pathogen
hepat
c
viru
hcv
hiv
reduc
less
one
transmiss
per
million
exposur
howev
approach
nearzero
infecti
diseas
risk
emerg
reemerg
pathogen
new
strategi
pathogen
inactiv
multipathogen
microarray
technolog
need
develop
refin
semin
hematol
elsevi
inc
right
reserv
e
merg
infect
sever
mechan
evolut
first
previous
unrecogn
human
agent
appear
de
novo
popul
often
adapt
anim
human
host
zoonot
transmiss
caus
devast
diseas
best
exemplifi
human
immunodefici
viru
hiv
evolv
simian
virus
africa
variant
creuztfeldjacob
diseas
vcjd
evolv
sequenti
prion
diseas
sheep
scrapi
cow
bovin
spongiform
encephalopathi
second
longrecogn
agent
emerg
new
diseas
threat
due
chang
popul
dynam
alter
migrat
pattern
intermedi
host
vector
exampl
west
nile
viru
wnv
infect
unit
state
due
migrat
suscept
bird
host
trypanosoma
cruzi
infect
chaga
diseas
follow
human
migrat
central
south
america
unit
state
agent
reemerg
emerg
creat
emerg
problem
third
establish
agent
present
emerg
problem
chang
environ
foster
growth
agent
vector
transfus
set
sepsi
occur
relat
room
temperatur
storag
platelet
facilit
bacteri
growth
fourth
exist
agent
caus
littl
human
diseas
may
emerg
threat
mutat
adapt
facilit
anim
human
human
human
spread
major
current
concern
categori
avian
flu
strain
potenti
creat
pandem
institut
medicin
defin
emerg
infect
new
reemerg
drugresist
infect
whose
incid
human
increas
within
past
two
decad
whose
incid
threaten
increas
near
futur
multipl
agent
fall
definit
known
potenti
transmit
blood
transfus
agent
travers
taxonom
classif
infecti
agent
caus
divers
constel
ill
tabl
summar
major
proven
suspect
emerg
transfusiontransmit
agent
panopli
agent
chosen
focu
exemplifi
differ
pattern
emerg
describ
specif
select
parasit
infect
due
malaria
babesia
spp
trypanosoma
cruzi
viral
infect
due
wnv
dengu
fever
viru
erythroviru
parvoviru
human
herp
avian
flu
viru
prion
diseas
vcjd
also
discuss
pathogen
reduct
strategi
transfus
product
concept
zerorisk
blood
suppli
malaria
caus
intraerythrocyt
protozoan
parasit
plasmodium
vivax
p
falciparum
p
oval
p
malaria
caus
clinic
ill
well
asymptomat
infect
p
falciparum
caus
sever
diseas
manifest
episod
fever
diaphores
also
sever
anemia
central
nervou
system
disturb
renal
failur
massiv
hemoglobinuria
black
water
fever
fatal
shock
syndrom
malari
infect
result
enorm
diseas
burden
annual
incid
mil
lion
case
worldwid
major
caus
infant
death
endem
region
anophel
mosquito
vector
transmiss
unit
state
receipt
blood
infect
asymptomat
donor
malariaendem
area
common
rout
direct
mosquito
bite
ancient
infect
malaria
includ
emerg
transfusiontransmit
infect
spread
endem
nonendem
region
result
escal
emigr
previous
remot
countri
facilit
increas
avail
air
travel
recurr
intern
conflict
transport
soldier
endem
area
malari
spread
transfus
also
foster
rel
long
asymptomat
parasitemia
four
major
malari
speci
howev
despit
constel
circumst
rel
transfusiontransmit
case
occur
center
diseas
control
cdc
report
transfusionassoci
case
unit
state
four
decad
averag
two
three
case
per
year
one
case
per
million
unit
transfus
number
may
underestim
true
infect
remain
undetect
other
remain
unreport
transfusiontransmit
malaria
remain
risk
latent
infect
p
falciparum
persist
averag
year
consider
longer
period
describ
infect
p
vivax
p
oval
persist
long
year
p
malaria
lifetim
malaria
also
bloodtransmit
risk
organ
surviv
least
week
c
surviv
frozen
red
cell
storag
blood
donor
screen
assay
malaria
current
licens
unit
state
antibodi
nucleic
acid
detect
strategi
feasibl
develop
would
high
costbenefit
ratio
former
might
low
specif
sensit
present
blood
bank
depend
donor
screen
question
exclud
person
risk
lifelong
temporari
resid
endem
area
donor
defer
follow
base
perman
resid
nonendem
countri
travel
endem
area
defin
cdc
defer
year
time
leav
endem
area
whether
receiv
antimalari
prophylaxi
provid
free
symptom
suggest
malaria
immigr
refuge
citizen
resid
endem
countri
defer
year
time
depart
endem
area
provid
free
symptom
suggest
malari
infect
person
histori
malaria
defer
year
symptom
longer
present
deferr
period
base
cdc
data
indic
malaria
case
travel
occur
within
year
leav
risk
area
case
perman
resid
endem
area
occur
within
year
leav
endem
area
deferr
effect
limit
transfusiontransmit
malaria
come
cost
mani
unnecessari
donor
deferr
age
travel
endem
area
quit
common
specif
sensit
assay
detect
parasitemia
would
spare
donor
though
high
cost
rel
benefit
number
differ
speci
babesia
worldwid
protozoan
parasit
class
piroplasmea
sporozoea
order
piroplasmida
loos
piroplasm
agent
resembl
malaria
parasit
babesiosi
may
mistakenli
diagnos
malaria
unit
state
b
microti
commonli
identifi
agent
although
b
divergen
also
present
least
two
unnam
speci
identifi
washington
california
respect
known
babesia
spp
infect
numer
mammalian
speci
transmit
tick
primarili
ixod
genu
b
microti
transmit
ixod
dammini
also
known
scapulari
blackleg
deer
tick
primari
mammalian
reservoir
whitefoot
mous
tick
may
also
transport
deer
b
microti
restrict
expand
geograph
rang
unit
state
larg
confin
northeastern
coastal
area
part
upper
midwest
includ
minnesota
wisconsin
b
divergen
also
identifi
us
state
tick
vector
identifi
human
alway
accident
host
acquir
infect
tickbit
frequent
goe
unnot
ixod
tick
small
tick
attach
host
day
order
effect
transmit
parasit
despit
global
distribut
babesia
spp
almost
report
case
transmiss
transfus
occur
unit
state
document
occurr
data
preval
babesia
infect
us
blood
donor
area
high
endem
reason
sound
northeast
unit
state
seropreval
b
microti
reportedli
rang
gener
popul
connecticut
patient
lyme
diseas
sever
report
b
microti
blood
donor
publish
rate
high
five
posit
shelter
island
ny
recent
connecticut
studi
report
blood
donor
seroposit
b
microti
perhap
import
seroposit
donor
studi
demonstr
parasitem
test
polymeras
chain
reaction
pcr
indic
obviou
transmiss
risk
rel
recent
find
parasitemia
may
quit
prolong
much
month
even
among
asymptomat
individu
estim
risk
transfusiontransmiss
high
one
everi
transfus
unit
highli
endem
area
connecticut
interestingli
transmiss
occur
platelet
compon
presum
contain
contamin
red
cell
incub
period
tick
bite
usual
week
occasion
long
month
manifest
rang
asymptomat
infect
fulmin
malarialik
infect
rare
may
fatal
symptom
gener
flulik
may
includ
malais
chill
myalgia
anemia
fatigu
fever
approach
patient
also
nausea
emesi
night
sweat
weight
loss
hematuria
believ
associ
high
level
parasitemia
hepatomegali
splenomegali
may
also
present
parasit
primarili
infect
erythrocyt
case
infect
diseas
acut
point
may
degre
chronic
immunocompromis
age
asplen
patient
particular
risk
develop
seriou
even
fatal
diseas
result
transfus
transmiss
agent
usual
selflimit
sever
case
treatabl
clindamycin
quinin
recent
combin
atovaquon
clindamycin
shown
effect
fewer
side
effect
diseas
manifest
potenti
exposur
histori
contribut
initi
diagnosi
exposur
may
inappar
histori
blood
transfus
particularli
endem
area
although
case
occur
result
blood
import
endem
area
may
rais
suspicion
laboratori
diagnosi
includ
examin
stain
blood
smear
test
antibodi
use
immunofluoresc
pcr
also
may
help
procedur
avail
investig
basi
donor
screen
test
current
avail
present
measur
effect
prevent
transfus
transmiss
babesia
histori
tickbit
would
appear
use
screen
neither
suffici
sensit
specif
travel
histori
suffer
problem
possibl
prolong
parasitemia
reduc
efficaci
restrict
donat
area
high
endem
tick
season
clinician
area
high
risk
awar
possibl
transfusionassoci
babesia
infect
treatment
chaga
diseas
caus
protozoan
parasit
trypanosoma
cruzi
parasit
infect
mani
mammalian
speci
includ
man
cruzi
similar
trypanosom
passag
number
differ
morpholog
form
depend
stage
life
cycl
parasit
transmit
reduvid
triatomin
bug
parasit
multipli
high
level
gut
bug
bug
fece
shed
feed
heavili
contamin
infect
least
human
usual
result
rub
insect
fece
site
bite
mucu
membran
congenit
infect
may
also
occur
infect
mother
recent
oral
transmiss
cruzi
document
area
endem
cruzi
blood
transfus
may
predomin
rout
human
infect
number
case
transmiss
organ
transplant
also
report
parasit
occur
continent
america
latitud
howev
condit
favor
natur
transmiss
human
gener
confin
part
latin
america
high
preval
infect
among
feral
domest
anim
vector
insect
tendenc
live
crack
fissur
roof
substandard
hous
seropreval
rate
vari
wide
may
high
part
bolivia
estim
million
infect
individu
live
south
central
america
part
mexico
mani
south
american
countri
signific
effort
reduc
risk
diseas
usual
aggress
use
insecticid
insid
home
underway
unit
state
although
rare
autochthon
infect
occur
major
human
infect
follow
immigr
individu
infect
elsewher
one
time
estim
legal
immigr
infect
number
may
much
higher
seropreval
studi
indic
blood
donor
may
seroposit
area
larg
number
migrant
lo
angel
miami
overal
us
preval
may
lower
mani
case
infect
lifelong
seroposit
donor
unit
state
parasitemia
demonstr
pcr
andor
cultur
despit
first
infect
mani
year
earlier
least
seven
case
transfus
transmiss
cruzi
document
unit
state
canada
three
four
cluster
infect
via
organ
transplant
immunocompromis
patient
seem
risk
seriou
fulmin
diseas
effort
identifi
transfus
transmiss
lookback
evalu
transfus
patient
reveal
addit
case
risk
infect
may
high
suggest
seropreval
rate
acut
diseas
gener
mild
treatabl
use
experiment
drug
nifurtimox
benznizadol
howev
drug
rel
seriou
sideeffect
unit
state
avail
cdc
infect
often
take
place
earli
life
individu
go
chronic
lifelong
infect
treat
although
chronic
infect
often
asymptomat
case
lead
seriou
fatal
cardiac
intestin
diseas
cardiac
infect
may
lead
arrhythmia
sudden
cardiac
death
less
frequent
infect
smooth
muscl
intestin
caus
megaesophagu
megacolon
parasit
may
visual
blood
infect
tissu
test
antibodi
cruzi
avail
commerci
refer
laboratori
indirect
immunofluoresc
eia
format
common
passiv
hemagglutin
assay
develop
commerci
varieti
confirmatori
test
avail
none
appear
gold
standard
unit
state
enzym
immunoassay
test
blood
screen
develop
one
like
licens
avail
us
blood
donor
ask
chaga
diseas
question
littl
valu
histori
birth
prolong
travel
endem
area
adequ
specif
would
decim
blood
suppli
locat
chaga
blood
screen
assay
like
employ
licens
limit
data
suggest
leukoreduct
may
effect
parasit
titer
blood
even
approach
would
offer
complet
protect
wnv
envelop
singlestrand
rna
flaviviru
japanes
enceph
group
wnv
primarili
infect
numer
speci
bird
act
amplifi
host
howev
mani
mammal
vertebr
infect
viru
transmit
mosquito
larg
culicin
man
accident
host
viru
confin
africa
southern
europ
part
middl
east
india
appear
unit
state
first
time
year
human
case
report
queen
ny
next
year
viru
spread
throughout
unit
state
canada
mexico
caribbean
date
peak
year
epidem
report
human
case
respect
estim
sever
hundr
thousand
individu
infect
year
fewer
case
seen
subsequ
year
risk
transfus
transmiss
estim
high
one
per
thousand
unit
area
time
peak
incid
document
case
transmiss
transfus
occur
result
nucleic
acid
test
nat
wnv
rna
implement
juli
test
identifi
potenti
infecti
compon
first
three
year
use
wnv
infect
asymptomat
approxim
case
west
nile
fever
occur
among
remaind
sometim
associ
headach
eye
pain
fatigu
muscl
ach
rash
symptom
may
last
day
sever
week
sever
diseas
usual
neuroinvas
may
manifest
sever
headach
high
fever
neck
stiff
stupor
disorient
coma
tremor
convuls
muscl
weak
paralysi
meningoenceph
may
fatal
common
person
age
immunocompromis
individu
estim
one
person
infect
wnv
develop
sever
diseas
fatal
lead
prolong
disabl
asymptomat
mild
diseas
viremia
report
persist
month
howev
rel
high
level
viremia
absenc
antibodi
rare
last
week
period
individu
might
infecti
via
blood
transfus
test
igm
antibodi
wnv
use
establish
laboratori
diagnosi
presenc
symptom
addit
viru
may
isol
vero
cell
pcr
nat
viral
rna
sensit
nat
use
blood
donor
screen
us
donor
defer
day
wnv
diseas
posit
test
dengu
viru
envelop
singlestrand
rna
viru
belong
flaviviru
group
particl
nm
diamet
four
serotyp
identifi
viru
transmit
mosquito
predominantli
aed
aegypti
albopictu
endem
tropic
human
primari
amplifi
host
although
monkey
may
also
infect
recent
larg
outbreak
dengu
occur
number
countri
particularli
southeast
asia
dengu
infect
produc
number
symptom
mani
similar
west
nile
fever
includ
fever
headach
eye
pain
rash
addit
often
sever
joint
muscl
pain
infect
one
strain
viru
result
effect
immun
respons
strain
second
infect
differ
strain
still
occur
second
infect
result
dengu
hemorrhag
fever
seriou
diseas
pronounc
symptom
accompani
hemorrhag
shock
syndrom
ensu
mortal
rate
high
welldocu
case
transfusiontransmiss
dengu
one
case
report
hong
kong
scientif
literatur
promedmail
octob
possibl
asymptomat
virem
phase
dengu
much
shorter
wnv
transfusiontransmit
case
like
would
recogn
context
larg
mosquitoborn
outbreak
possibl
instanc
dengu
transmiss
bone
marrow
transplant
recipi
puerto
rico
unclear
case
truli
obviou
intervent
manag
potenti
transfusiontransmit
dengu
nat
screen
test
could
develop
implement
intervent
necessari
strategi
would
prefer
prohibit
blood
collect
implement
northern
queensland
australia
result
introduct
dengu
area
parvoviru
merit
discuss
newli
emerg
agent
potenti
sever
patholog
effect
becom
appar
past
decad
widespread
use
pool
plasma
compon
foster
spread
transfus
parvoviru
inactiv
solvent
deterg
method
render
pool
plasma
free
major
lipidenvelop
agent
increas
number
immunocompromis
blood
recipi
suscept
prolong
viremia
seriou
bone
marrow
depress
effect
agent
make
infect
wide
appreci
parvoviru
design
erythroviru
member
parvovirida
famili
small
nm
nonenvelop
singlestrand
dna
virus
parvovirida
infect
mani
insect
anim
speci
associ
signific
human
diseas
major
cellular
receptor
parvoviru
globosid
glycosphingolipid
found
predominantli
erythroid
cell
progenitor
interestingli
glycosphingolipid
constitut
viral
receptor
longrecogn
p
antigen
red
cell
rare
individu
lack
p
antigen
red
cell
p
tjaphenotyp
resist
infect
parvoviru
respons
common
benign
exanthema
children
known
erythema
infectiosum
fifth
diseas
significantli
infect
erythropoiet
progenitor
cell
caus
transient
sometim
profound
aplast
crisi
patient
underli
hemolyt
syndrom
particularli
sickl
cell
anemia
hereditari
spherocytosi
inde
aplast
crisi
occur
patient
known
hemolyt
anemia
preponderantli
due
parvoviru
sometim
compens
hemolyt
anemia
first
recogn
superimpos
transient
aplast
crisi
addit
parvoviru
caus
sever
prolong
red
cell
aplasia
patient
congenit
acquir
immunodefici
patient
persist
highlevel
viremia
absenc
antibodi
number
red
blood
cell
precursor
lyse
durat
virem
destruct
phase
immunocompet
individu
underli
hemolyt
state
usual
insuffici
caus
detect
anemia
temporarili
decreas
red
cell
product
demonstr
parvoviru
caus
fatal
hydrop
fetali
especi
fetu
infect
second
trimest
parvoviru
infect
respons
estim
case
nonimmun
hydrop
fetali
adult
especi
women
associ
arthropathi
occur
arthropathi
usual
transient
persist
recur
even
absenc
detect
viremia
surprisingli
parvoviru
infect
also
associ
neutropenia
frank
agranulocytosi
thrombocytopenia
whether
associ
cytopenia
indic
permiss
receptor
nonerythroid
progenitor
simpli
bystand
effect
unknown
parvoviru
transmiss
common
spring
predominantli
respiratorydroplet
rout
transmiss
like
high
virem
phase
preced
clinic
diseas
secondari
transmiss
household
school
effici
parvoviru
infect
unequivoc
spread
blood
transfus
particularli
pool
plasma
compon
number
transmiss
compar
number
infect
small
virem
individu
lowtit
viru
coexist
neutral
antibodi
igm
antibodi
appear
day
infect
persist
sever
month
neutral
igg
antibodi
gener
appear
week
infect
persist
life
protect
role
antibodi
parvoviru
demonstr
efficaci
commerci
immunoglobulin
use
treat
infect
immunocompromis
subject
recipi
infect
stem
primarili
donor
earli
infect
high
level
viremia
either
absenc
antibodi
far
excess
neutral
potenti
emerg
antibodi
absenc
antibodi
viral
level
high
copiesml
although
preval
parvoviru
viremia
donor
report
rang
three
case
anemia
associ
blood
transfus
report
unit
state
europ
period
although
frequenc
clinic
signific
parvoviru
infect
low
sever
clinic
consequ
person
hemolyt
anemia
immunodefici
warrant
prevent
measur
possibl
antiparvoviru
antibodi
preval
popul
util
donor
screen
assay
thu
detect
depend
nucleic
acid
amplif
current
requir
perform
nat
standard
blood
compon
unlik
recommend
forthcom
howev
sinc
greatest
risk
product
pool
plasma
commerci
plasma
fraction
elect
perform
parvoviru
nat
test
use
detun
insensit
assay
detect
level
viru
greater
copiesml
note
low
level
viremia
exist
primarili
presenc
coexist
neutral
antibodi
high
level
viru
transmit
infect
caus
diseas
suscept
recipi
perhap
main
emerg
concern
immunosuppress
individu
constitut
increas
proport
patient
requir
blood
product
even
rel
low
frequenc
transmiss
popul
could
devast
consequ
viru
also
pose
particular
threat
fetu
rais
special
concern
utero
transfus
matern
transfus
earli
pregnanc
etiolog
agent
kaposi
sarcoma
account
name
kaposi
sarcomaassoci
herp
viru
kshv
formal
gamma
herpesviru
envelop
doublestrand
dna
viral
particl
nm
diamet
viru
natur
transmit
though
saliva
sexual
exposur
also
transmit
organ
transplant
signific
controversi
accuraci
avail
serolog
test
infect
preval
uncertain
use
ifa
donor
popul
unit
state
antibodi
preval
significantli
lower
human
herpesvirus
much
higher
rate
seen
among
patient
kaposi
sarcoma
hivposit
male
homosexu
preval
also
higher
area
africa
southeast
europ
high
frequenc
classic
kaposi
sarcoma
unclear
whether
particular
group
patient
increas
risk
clinic
diseas
appear
kaposi
sarcoma
organ
transplant
recipi
suggest
immunocompromis
patient
may
increas
risk
transmiss
transfus
unequivoc
establish
seem
like
number
studi
shown
increas
preval
infect
intraven
drug
user
select
transfus
popul
along
convinc
evid
transfusionassoci
seroconvers
dollard
colleagu
http
provid
best
evid
date
transfusiontransmiss
larg
studi
conduct
africa
etiolog
agent
kaposi
sarcoma
perhap
prolif
diseas
multicentr
castleman
diseas
patholog
mechan
poorli
understood
presum
consist
prolif
diseas
caus
herp
virus
infect
chronic
result
diseas
occur
requir
mani
year
develop
infect
like
asymptomat
inform
acut
manifest
infect
among
asymptomat
seroposit
individu
detect
viral
dna
pcr
infrequ
infect
identifi
sever
serolog
assay
antibodi
supplement
pcr
viral
dna
test
current
avail
blood
bank
screen
agreement
whether
screen
necessari
desir
blood
infect
individu
probabl
transfus
mani
year
without
document
obviou
advers
outcom
cellassoci
potenti
infect
reduc
elimin
leukoreduct
avian
influenza
viru
strain
singlestrand
envelop
rna
viru
famili
orthomyxovirida
genu
influenza
viru
influenza
strain
classifi
surfac
hemagglutinin
h
sequenc
h
essenti
bind
host
receptor
neuraminidas
n
sequenc
avian
influenza
virus
typic
infect
human
hemagglutinin
configur
bind
human
receptor
respiratori
epithelium
avian
flu
due
strain
emerg
massiv
epidem
among
chicken
fowl
eastern
southeast
asia
migrat
pattern
bird
spread
global
million
commerci
fowl
slaughter
contain
epidem
transmiss
bird
human
increasingli
document
almost
alway
among
person
direct
contact
infect
fowl
human
human
transmiss
limit
household
cluster
one
case
appar
childtomoth
transmiss
serolog
studi
among
household
contact
expos
healthcar
worker
support
effici
human
human
spread
nonetheless
great
concern
agent
mutat
random
combin
easili
spread
among
human
rais
specter
global
influenza
pandem
govern
public
health
servic
throughout
world
prepar
eventu
believ
inevit
other
consid
highli
unlik
differ
opinion
hing
recombinatori
event
would
foster
respiratori
spread
similar
seen
annual
wave
season
flu
anticip
deadli
season
flu
strain
appar
caus
fatal
infect
small
number
human
far
infect
death
rate
among
infant
young
particularli
high
one
studi
thailand
report
mortal
among
hospit
children
death
usual
due
progress
respiratori
failur
acut
respiratori
distress
syndrom
multiorgan
failur
also
occur
although
viru
effici
transmit
among
human
omin
sign
appear
sinc
avian
epidem
emerg
increas
viral
virul
factor
enhanc
replic
capabl
increas
resist
interferon
tumor
necrosi
expand
host
rang
avian
speci
abil
infect
felid
enhanc
pathogen
experiment
infect
mice
ferret
increas
stabil
environ
also
worrisom
observ
presag
evolv
adapt
viru
may
prime
human
outbreak
research
institut
pharmaceut
industri
work
frantic
develop
new
therapeut
vaccin
cellbas
vaccin
system
could
adapt
rapidli
whatev
flu
strain
next
emerg
midst
concern
activ
blood
transfus
servic
ponder
effect
flu
pandem
would
blood
suppli
whether
influenza
bloodtransmiss
diseas
evid
blood
transmiss
scant
transfusiontransmit
case
report
appar
brief
viremia
make
transmiss
possibl
known
involv
liver
kidney
suggest
hematogen
spread
lung
absenc
evid
contrari
safest
assum
avian
flu
bloodtransmit
howev
asymptomat
period
viremia
may
short
number
blood
transmiss
small
even
pandem
occur
plasma
compon
commerci
plasma
fraction
safe
due
inactiv
procedur
alreadi
place
larger
problem
disrupt
blood
suppli
engend
larg
number
donor
stricken
diseas
perhap
quarantin
measur
invok
also
estim
one
third
blood
bank
staff
infect
transport
system
put
enorm
stress
whole
process
blood
collect
deliveri
current
blood
screen
measur
avail
even
practic
nucleic
acid
assay
develop
would
littl
impact
number
virem
donor
small
number
donor
inelig
ill
number
staff
unavail
infect
larg
larger
problem
blood
deliveri
blood
safeti
variant
creutzfeld
jakob
diseas
vcjd
new
prion
diseas
man
first
describ
unit
kingdom
result
consum
tissu
cattl
affect
bovin
spongiform
encephalopathi
bse
mad
cow
diseas
caus
agent
gener
accept
prion
conform
variant
natur
occur
protein
specifi
prp
gene
patholog
protein
proteaseresist
thu
subject
normal
process
degrad
remov
furthermor
patholog
conform
catalys
chang
copi
protein
process
simul
replic
modifi
protein
form
fibrou
aggreg
appear
involv
pathogenesi
diseas
unlik
classic
cjd
larg
although
exclus
sporad
natur
vcjd
etiolog
link
bse
cattl
emerg
follow
appear
cattl
diseas
year
time
write
case
human
diseas
recogn
unit
kingdom
case
elsewher
world
number
latter
case
attribut
dietari
exposur
england
bovin
diseas
appear
mani
part
world
albeit
much
lower
number
hundr
thousand
case
seen
unit
kingdom
strenuou
effort
reduc
incid
cattl
diseas
current
annual
number
human
case
also
declin
unlik
classic
cjd
three
case
transmiss
vcjd
blood
transfus
document
develop
diseas
detect
diseas
agent
patient
transfus
blood
individu
subsequ
develop
vcjdrelat
dementia
die
three
case
occur
england
http
wwwhpaorgukhpanewsarticl
press
secondari
rout
transmiss
recogn
effort
made
estim
number
peopl
harbor
infecti
prion
assess
excis
tonsil
appendic
one
publish
studi
agent
found
three
test
vcjd
rel
slow
onset
character
disturb
mentat
dementia
ataxia
myoclonu
eventu
coma
death
symptom
neurophatholog
find
differ
classic
cjd
onset
usual
earlier
life
suspicion
case
occur
age
pathophysiolog
spongiform
degrad
brain
characterist
vacuol
socal
florid
plaqu
progress
death
inevit
usual
month
year
clinic
onset
long
infecti
agent
present
patient
clinic
manifest
unknown
transfus
transmiss
occur
donat
collect
long
year
prior
appear
frank
diseas
definit
premortem
diagnost
test
preliminari
diagnosi
may
made
basi
symptom
age
definit
diagnosi
depend
patholog
examin
brain
immunohistochemistri
identifi
presenc
proteaseresist
prion
addit
test
particularli
glycoform
establish
whether
agent
vcjd
test
avail
detect
infecti
prion
blood
asymptomat
individu
primari
intervent
unit
state
indefinit
defer
present
donor
histori
visit
bseaffect
european
countri
period
like
exposur
individu
receiv
blood
transfus
unit
kingdom
treat
europeanderiv
bovin
insulin
also
defer
polici
substanti
impact
upon
blood
avail
us
addit
assay
develop
ongo
effort
develop
affin
filter
may
use
reduc
prion
content
red
cell
concentr
agent
mani
infecti
agent
potenti
transmit
transfus
asymptomat
bloodborn
phase
may
surviv
blood
compon
process
storag
past
year
degre
concern
number
emerg
agent
case
intervent
implement
unusu
viscer
present
leishmania
infect
among
troop
involv
conflict
persian
gulf
countri
along
evid
transmiss
led
temporari
deferr
returne
iraq
potenti
case
transmiss
anaplasma
phagocytophilum
agent
human
granulocyt
ehrlichosi
rais
interest
tickborn
infect
led
intervent
contrast
deferr
measur
rapidli
implement
global
outbreak
sever
acut
respiratori
syndrom
sar
despit
absenc
evid
transfusiontransmiss
concern
express
find
simian
foami
viru
sfv
infect
anim
handler
exampl
interspeci
transmiss
retrovirusan
event
thought
reflect
origin
aid
human
popul
although
lookback
studi
show
transmiss
sfv
blood
donat
infect
anim
handler
although
sfv
appear
caus
diseas
human
regulatori
offici
discuss
need
deferr
monkey
handler
polici
implement
canada
rational
interspeci
transfer
virus
might
accompani
mutat
event
lead
newli
pathogen
form
genet
variant
exist
agent
particularli
hiv
hepat
b
viru
hbv
continu
appear
variant
may
escap
detect
current
method
sever
agent
identifi
molecular
viral
discoveri
program
propos
caus
nona
hepat
includ
close
relat
flavivirus
gb
viru
type
c
gbvc
hepat
g
viru
hgv
new
circovirus
tt
viru
ttv
sen
viru
senv
care
clinic
epidemiolog
studi
shown
agent
caus
human
hepat
present
agent
search
diseas
final
continu
attent
possibl
hemorrhag
fever
virus
transmiss
transfus
concern
also
extend
addit
agent
might
use
bioterrorist
attack
continu
emerg
new
infecti
agent
old
agent
creat
emerg
problem
present
recurr
dilemma
blood
transfus
servic
new
threat
rais
need
develop
new
donor
screen
assay
introduc
exclusionari
question
donor
screen
histori
margin
limit
blood
suppli
despit
extens
donor
test
detail
donor
histori
remain
bloodtransmiss
agent
intervent
place
linger
fear
new
agent
devast
potenti
hiv
emerg
futur
one
answer
escal
array
test
risk
factor
exclus
develop
implement
strategi
univers
pathogen
inactiv
would
reduc
elimin
risk
known
pathogen
would
preemptiv
destroy
signific
pathogen
might
emerg
futur
concept
physicochem
pathogen
reduct
develop
past
two
decad
greatest
success
thu
far
use
solventdeterg
sd
combin
destroy
envelop
virus
includ
hiv
human
tlymphotrop
viru
htlv
hbv
hepat
c
viru
hcv
transmiss
agent
sdtreat
plasma
deriv
report
sinc
process
implement
protect
commerci
plasma
suppli
west
nile
viru
wnv
epidem
prove
valu
preemptiv
strategi
also
demonstr
weak
sd
method
sd
inactiv
lipidenvelop
agent
appli
red
cell
platelet
product
whose
function
depend
intact
lipid
membran
clear
need
exist
broad
spectrum
inactiv
method
could
appli
cellular
well
liquid
compon
blood
toward
end
mani
physicochem
method
inactiv
nucleic
acid
explor
prize
goal
blood
safeti
would
method
inactiv
virus
regardless
nucleic
acid
structur
well
bacteria
parasit
potenti
replic
infecti
organ
addit
technolog
inactiv
lymphocyt
prevent
fatal
transfusionassoci
graftversushost
reaction
prion
would
escap
diseasecaus
abnorm
fold
protein
contain
nucleic
acid
mani
nucleic
acidinactiv
agent
investig
depend
interact
effector
chemic
extern
light
sourc
system
extens
studi
synthet
trimethylpsoralen
design
combin
longwav
ultraviolet
light
plasma
platelet
product
combin
inactiv
test
virus
bacteria
whether
dna
rna
envelop
nonenvelop
level
limit
detect
accept
mainten
plasma
protein
level
platelet
function
much
loss
platelet
yield
altern
psoralen
inactiv
infecti
agent
platelet
product
vitamin
riboflavin
b
presenc
ultraviolet
seemingli
safer
natur
vitamin
shown
broad
inactiv
potenti
may
still
reduc
platelet
surviv
one
major
disadvantag
psoralen
riboflavin
use
effect
inactiv
red
cell
product
due
poor
penetr
light
dens
materi
approach
employ
inactiv
virus
red
cell
product
frangibl
anchorlinkereffector
compound
frale
crosslink
nucleic
acid
absenc
light
howev
alkyl
agent
potenti
toxic
blood
recipi
also
handl
blood
product
even
risk
theoret
real
potenti
risk
may
prevent
frale
alkyl
agent
ethyleneimin
inactin
use
blood
bank
set
addit
potenti
toxic
implement
viral
inactiv
strategi
routin
blood
bank
use
limit
singl
method
use
blood
compon
high
cost
econom
issu
amelior
effect
inactiv
would
obviat
need
exist
blood
screen
assay
requir
introduc
new
assay
emerg
agent
perhap
also
avoid
costli
leukoreduct
thu
rel
impract
high
cost
exist
techniqu
deter
continu
research
toward
ideal
method
would
inactiv
nucleic
acid
blood
compon
singl
process
provid
unpreced
level
blood
safeti
never
zerorisk
blood
suppli
sinc
problem
extend
beyond
infecti
diseas
transmiss
remov
almost
infecti
agent
singl
inactiv
process
goal
attract
abandon
without
intens
explor
continu
small
measur
risk
transmiss
infecti
agent
blood
transfus
even
case
hiv
aggress
intervent
undertaken
addit
discuss
emerg
agent
present
new
threat
blood
safeti
even
though
risk
transmiss
almost
invari
much
lower
risk
advers
outcom
medic
intervent
pervas
pressur
minim
even
elimin
transfusiontransmit
infect
numer
studi
shown
margin
cost
measur
far
exceed
gener
accept
norm
costeffect
approach
driven
increasingli
conserv
applic
precautionari
principl
without
incorpor
usual
modifi
guidanc
zerorisk
blood
suppli
may
achiev
clear
solut
dilemma
defin
accept
risk
case
resourc
limit
defin
extent
avail
intervent
circumst
impact
intervent
upon
blood
avail
must
balanc
gain
safeti
done
develop
deferr
criteria
unit
state
donor
exposur
risk
exposur
bse
final
even
technolog
like
pathogen
reduct
might
offer
elimin
infect
may
low
tangibl
toxic
risk
patient
